Ngā hua rapu - Matthew D. Hellmann

Whakamahine hua
  1. 1
    PD-1/PD-L1 Axis in Lung Cancer

    PD-1/PD-L1 Axis in Lung Cancer mā Fernando C. Santini, Matthew D. Hellmann

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Acquired Resistance to Immune Checkpoint Inhibitors

    Acquired Resistance to Immune Checkpoint Inhibitors mā Adam J. Schoenfeld, Matthew D. Hellmann

    I whakaputaina 2020
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Chemotherapy remains an essential element of personalized care for persons with lung cancers

    Chemotherapy remains an essential element of personalized care for persons with lung cancers mā Matthew D. Hellmann, Bingyu Li, Jamie E. Chaft, Mark G. Kris

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer

    How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer mā Solange Peters, M. Reck, Egbert F. Smit, Tony Mok, Matthew D. Hellmann

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Opportunistic infections in patients treated with immunotherapy for cancer

    Opportunistic infections in patients treated with immunotherapy for cancer mā Chrisann Kyi, Matthew D. Hellmann, Jedd D. Wolchok, Paul B. Chapman, Michael A. Postow

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors

    Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors mā Jamie E. Chaft, Matthew D. Hellmann, Moises J. Velez, William D. Travis, Valerie W. Rusch

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

    Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers mā Jia Luo, Hira Rizvi, Jacklynn V. Egger, Isabel R. Preeshagul, Jedd D. Wolchok, Matthew D. Hellmann

    I whakaputaina 2020
    Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

    Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing mā Helena A. Yu, Maria E. Arcila, Matthew D. Hellmann, Mark G. Kris, Marc Ladanyi, Gregory J. Riely

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics

    Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics mā Gregory S. Phillips, Azael Freites‐Martínez, Jennifer Wu, Donald Chan, Gabriella Fabbrocini, Matthew D. Hellmann, Mario E. Lacouture

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma

    Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma mā Jeremy S. Abramson, Matthew D. Hellmann, Jeffrey A. Barnes, Peter S. Hammerman, Christiana E. Toomey, Tak Takvorian, Alona Muzikansky, Ephraim P. Hochberg

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images

    Multiple Resolution Residually Connected Feature Streams for Automatic Lung Tumor Segmentation From CT Images mā Jue Jiang, Yu‐Chi Hu, Chia‐Ju Liu, Darragh Halpenny, Matthew D. Hellmann, Joseph O. Deasy, G Mageras, Harini Veeraraghavan

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas

    Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas mā Juliana Schilsky, Ai Ni, Linda S. Ahn, Sutirtha Datta, William D. Travis, Mark G. Kris, Jamie E. Chaft, Natasha Rekhtman, Matthew D. Hellmann

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types

    Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types mā Aparna Chhibber, Lingkang Huang, Hong Zhang, Jialin Xu, Rǎzvan Cristescu, Xiao Liu, Devan V. Mehrotra, Judong Shen, Peter Shaw, Matthew D. Hellmann, Alexandra Snyder

    I whakaputaina 2022
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas

    Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas mā Juliana Eng, Kaitlin M. Woo, Camelia S. Sima, Andrew J. Plodkowski, Matthew D. Hellmann, Jamie E. Chaft, Mark G. Kris, Maria E. Arcila, Marc Ladanyi, Alexander Drilon

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    PS2 CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden

    PS2 CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden mā Clarissa Mathias, Martin Reck, Matthew D. Hellmann, Suresh S. Ramalingam, Julie R. Brahmer, Kenneth J. O’Byrne, Prabhu Bhagavatheeswaran, Faith E. Nathan, Hossein Borghaei, Luis Paz‐Ares

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

    Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib mā Adam J. Schoenfeld, Kathryn C. Arbour, Hira Rizvi, Afsheen Iqbal, Shirish M. Gadgeel, Jeffrey Girshman, Mark G. Kris, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

    Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade mā Tavi Nathanson, Arun Ahuja, Alex Rubinsteyn, Bülent Arman Aksoy, Matthew D. Hellmann, Diana Miao, Eliezer M. Van Allen, Taha Merghoub, Jedd D. Wolchok, Alexandra Snyder, Jeff Hammerbacher

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC

    Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC mā Laurent Dercle, Matthew Fronheiser, Naiyer A. Rizvi, Matthew D. Hellmann, Sabine Maier, Wendy Hayes, Hao Yang, Pingzhen Guo, Tito Fojo, Lawrence H. Schwartz, Binsheng Zhao, David Leung

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

    Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers mā Anya M. Litvak, Paul K. Paik, Kaitlin M. Woo, Camelia S. Sima, Matthew D. Hellmann, Maria E. Arcila, Marc Ladanyi, Charles M. Rudin, Mark G. Kris, Gregory J. Riely

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

    Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders mā Giulia C. Leonardi, Justin F. Gainor, Mehmet Altan, Sasha Kravets, Suzanne E. Dahlberg, Lydia Gedmintas, Roxana Azimi, Hira Rizvi, Jonathan W. Riess, Matthew D. Hellmann, Mark M. Awad

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: